Menu Search
Equities

Crinetics Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
6Z4:STU

Crinetics Pharmaceuticals Inc

Actions
  • Price (EUR)40.20
  • Today's Change0.20 / 0.50%
  • Shares traded0.00
  • 1 Year change+19.64%
  • Beta0.1997
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

  • Revenue in USD (TTM)1.54m
  • Net income in USD-423.10m
  • Incorporated2008
  • Employees437.00
  • Location
    Crinetics Pharmaceuticals Inc6055 Lusk Blvd.SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 450-6464
  • Fax+1 (302) 636-5454
  • Websitehttps://www.crinetics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.